Hurvitz Chaim 4/A
4/A · NRX Pharmaceuticals, Inc. · Filed Nov 23, 2022
Insider Transaction Report
Form 4/AAmended
Hurvitz Chaim
Director
Transactions
- Purchase
Common Stock
2022-11-18$1.10/sh+40,408$44,449→ 500,000 total - Purchase
Common Stock
2022-11-17$1.08/sh+171,780$185,522→ 459,592 total - Purchase
Common Stock
2022-11-16$0.99/sh+287,812$284,934→ 287,812 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.00 to $0.93. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
- [F2]The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
- [F3]The original Form 4 disclosed that the price reported in Column 4 is a weighted average price. This Form 4/A is being filed to amend such information. The shares were purchased in a single transaction at $1.10.